Turn Therapeutics Inc. (TTRX) – What Are Brokerages Thinking About This Stock?

Turn Therapeutics Inc. (NASDAQ:TTRX) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, one has issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $9.00.

A number of equities analysts recently weighed in on the company. Lucid Cap Mkts upgraded Turn Therapeutics to a “strong-buy” rating in a research report on Thursday, September 24th. Zacks Research raised Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. WBB Securities restated a “sell” rating and set a $10.00 price objective on shares of Turn Therapeutics in a report on Monday, September 14th. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Finally, Wall Street Zen raised shares of Turn Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TTRX. Jefferies Financial Group Inc. acquired a new stake in shares of Turn Therapeutics during the second quarter valued at approximately $119,000. Bank of America Corp DE purchased a new stake in shares of Turn Therapeutics in the 2nd quarter valued at approximately $103,000. Ieq Capital LLC purchased a new stake in shares of Turn Therapeutics in the 2nd quarter valued at approximately $1,660,000. BlackRock Inc. purchased a new stake in shares of Turn Therapeutics in the 2nd quarter valued at approximately $282,000. Finally, Bridgewater Advisors Inc. acquired a new position in Turn Therapeutics in the 2nd quarter worth approximately $242,000.

Turn Therapeutics Price Performance

TTRX opened at $10.60 on Friday. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19. The business has a fifty day simple moving average of $11.52 and a 200-day simple moving average of $7.77. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $16.45.

Turn Therapeutics (NASDAQ:TTRX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. On average, equities analysts predict that Turn Therapeutics will post -0.40 earnings per share for the current year.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.